Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADG206 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ADG206 dose escalation | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ADG206 | DRUG | All participants in this study will receive the study drug ADG206 in one of the designed dosage level. ADG206 will be administered by intravenous infusion over 60-90 minutes on Day 1 of each treatment cycle until disease progression, intolerable toxicities or withdrawal of consent, or up to 2 years. |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status ≤1. * Subjects with advanced or metastatic solid tumors (except thymic tumors), which have progressed after all standard therapies, or no further standard therapies exists. * At least 1 measurable lesion per Response...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ADG206 is an investigational small molecule being developed for the treatment of advanced or metastatic solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with advanced or metastatic solid tumors who are at least 18 years old.
ADG206 targets CD137, a protein that plays a role in immune system regulation. By targeting CD137, ADG206 is designed to modulate immune responses in the context of cancer treatment. This mechanism is being investigated for its potential to treat advanced or metastatic solid tumors.
ADG206 is being developed by Adagene Inc., a biopharmaceutical company. Adagene Inc. is publicly traded under the ticker symbol ADAG. The company is conducting clinical research to evaluate the safety and efficacy of ADG206 in patients with advanced or metastatic solid tumors.
ADG206 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities for commercial use. The Phase 1 trial is designed to assess the safety, tolerability, and preliminary efficacy of ADG206 in patients with advanced or metastatic solid tumors.
ADG206 is being studied in a Phase 1 clinical trial with the identifier NCT05614258. This trial is titled 'Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors' and is being conducted in Australia. The study is currently active but not recruiting participants, with a planned enrollment of 14 patients.
ADG206 is a distinct investigational drug being developed by Adagene Inc. It is not known to be the same as any other approved or investigational drug. Its unique mechanism of targeting CD137 distinguishes it from other cancer therapies currently in development.